Radioimmunotherapy Consolidation using (131)I-Tositumomab for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission.

Publication Type:

Journal Article


Leukemia & lymphoma, Volume 57, Issue 3, p.572-6 (2015)




Despite initial responses to chemoimmunotherapy, relapse and minimal residual disease (MRD) remain major issues in treatment of CLL/SLL patients. We administered 131I-tositumomab to patients in CR or PR after induction chemotherapy. Toxicities and rate of PR to CR conversion and MRD elimination were assessed three months later. The study stopped prematurely after enrolling 16 patients .Four (25%) were in CR, 12 (75%) in PR, and 12 (75%) had MRD. Three months after treatment with 131I-tositumomab, CR was achieved (n=8; 50%) or sustained (n=4; 25%) in 12 patients and MRD was eliminated in 4 of 12 patients (33%). Hematologic toxicities were anemia in 1 patient (6%), neutropenia in 13 (81%), and thrombocytopenia in 8 (50%). Two patients (12%) developed MDS 17 and 20 months after consolidation. Consolidation with 131I-tositumomab for CLL/SLL patients in first remission is feasible and may provide the benefit of converting PR to CR and/or eliminating MRD.